Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Edward Thomas Ryan, D.T.M.&H., M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture
Other Positions
Title
Institution
Department

Overview
Edward T. Ryan, M.D. is the Director of Global Infectious Diseases, Massachusetts General Hospital, Boston, MA, Professor of Medicine, Harvard Medical School, and Professor of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health. Dr. Ryan received his Bachelor's degree in Biochemical Sciences from Princeton University, and a Doctorate in Medicine from Harvard University. He performed medical residency and fellowship training in infectious diseases at the Massachusetts General Hospital. Dr. Ryan received additional training in tropical medicine and infectious diseases at the London School of Hygiene & Tropical Medicine, was a Fellow in Human Rights & Medicine, Columbia University, and was an International Fellow, International Centre for Diarrhoeal Disease Research (ICDDR, B), Dhaka, Bangladesh.

Dr. Ryan has served on expert and advisory committees for the Institute of Medicine-National Academy of Sciences, U.S. Centers for Disease Control & Prevention, chaired the Clinical Research and Field Studies of Infectious Diseases Study section of the US NIH from 2006-2008, chaired the Standards and Treatment Guidelines Committee of the American Society of Tropical Medicine & Hygiene (ASTMH) 2010-2018, and served as ASTMH President from 2009-2010. Dr. Ryan has been elected to Fellowship of the American College of Physicians, the Infectious Diseases Society of America, the American Society of Tropical Medicine and Hygiene, and the American Academy of Microbiology. Dr Ryan has published over 300 peer-reviewed journal articles and book chapters on global infectious diseases, enteric infections, vaccines, and tropical medicine. Dr. Ryan is a Senior Editor of Hunter's Tropical Medicine, and a Medical Editor of the Centers for Disease Control and Prevention Yellow Book.

Research:

Our research focuses on host-bacterial pathogen interactions and immune responses, with a particular focus on enteric infections and the development of vaccines protective against enteric infections, and development of diagnostic assays. Specific focus areas include Vibrio cholerae, the cause of cholera; Salmonella enterica, the causes of typhoid and paratyphoid fever; and Shigella spp, the cause of dysentery. We work in collaborative efforts with researchers at the International Centre for Diarrhoeal Disease Research in Dhaka Bangladesh (ICDDR,B), as well as with colleagues in Nepal, Pakistan, Haiti, and South Sudan.

Immune responses during cholera

In a collaborative effort with researchers at the International Centre for Diarrhoeal Disease Research in Dhaka, Bangladesh (ICDDR,B), we are evaluating immune responses in humans infected with Vibrio cholerae, the cause of cholera. V. cholerae is endemic in over 50 countries, infects approximately 3-5 million individuals globally, and results in the death of approximately 100,000 individuals each year. Individuals most affected by cholera are those most impoverished, especially those lacking safe water and sanitary facilities, as well as individuals displaced by war, famine, disasters, and conflict. Cholera can be explosively epidemic, and the global burden of cholera may well increase with climate change, severe weather events, and increasing urbanization. V. cholerae is a human-restricted infection, and current cholera vaccines provide relatively short-term protection against disease. The mediators of protective immunity against cholera are poorly understood. To address this, we are applying a number of high throughput and platform technologies to assess innate and adaptive immune responses in humans with cholera and their household contacts, stratifying responses in the latter by subsequent protection from disease, and comparing responses in the former to those that occur in recipients of current cholera vaccines. The goal of these studies is to identify the mediators of protection against cholera, in order to advance improved prevention strategies, as well as to advance vaccine development and deployment.

Host-pathogen interactions during typhoid fever

In a collaborative effort with researchers at the International Centre for Diarrhoeal Disease Research in Dhaka, Bangladesh (ICDDR,B), we are evaluating host-pathogen interactions and immune responses in humans infected with Salmonella enterica serotype Typhi (the cause of typhoid fever) and S. Paratyphi (the cause of paratyphoid fever). Together, S. Typhi and S. Paratyphi cause approximately 20 million cases of enteric fever world-wide, resulting in approximately 200,000 deaths each year. Most of these deaths occur in impoverished children and young adults. Although usually caused by S. Typhi, one in four cases of enteric fever is caused by S. Paratyphi in many areas of the world. S. Typhi and S. Paratyphi are particularly common among urban residents in informal settlements and slums, although any individual lacking safe water and sanitary facilities is at risk of infection. Vaccines against S. Typhi provide only 50-60% protection against disease for 2-5 years, and, at present, there is no commercially available vaccine against S. Paratyphi. There is also no good point-of-care test to diagnose individuals with enteric fever, and S. Typhi and S. Paratyphi are becoming increasingly resistant to antimicrobial agents.To address this, we are evaluating host-pathogen interactions directly in humans infected with S. Typhi and S. Paratyphi. We are applying a number of technologies to evaluate innate and adaptive immune responses directly in humans infected with S. Typhi and S. Paratyphi in Bangladesh, and we are evaluating bacterial responses in humans during these human-restricted infections. The goal of these studies is to develop improved diagnostic assays, antimicrobial agents, and preventative strategies against these infections.

Immunization approaches for enteric infection

A fundamental challenge facing many enteric and mucosal vaccines is their inability to induce long-term protective immunity. Many of these vaccines may not be prominent inducers of memory cells, which play critical roles in mediating long-term protection against disease. Using our analysis of memory B and T cell induction during wild-type human enteric infection in Bangladesh, we are evaluating the ability of a number of vaccination approaches and strategies to induce long-term memory responses protective against mucosal and enteric infections, including development of enteric conjugate vaccines, and analysis of oral-transcutaneous prime-boosting approaches.

Global TravEpinet (GTEN)

To extend our analysis of infections associated with living in, traveling through, or immigrating from resource-limited areas, we also work with the U.S. Centers for Disease Control and Prevention through the GTEN (Global TravEpiNet; Global Travelers' Epidemiology Network) Program. GTEN's mission is to advance the health of American residents who travel internationally, as well as to lessen the likelihood of disease importation into home communities. GTEN-relate resources are available at Heading Home Healthy. Through this program, we have been able to address COVID-19, an illness introduced into U.S. populations through travel. Our efforts have focused on understanding diagnostic assays and transmission dynamics to assist in control measures. We have assessed immune responses during SARS-CoV-2 infection, including duration and cross reactivity with other coronaviridae, characterized immune responses during naturally acquired disease to inform vaccine development, and phylogenetically typed viral strains to assess introduction and transmission of SARS-CoV-2 at population levels.

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Akter A, Ahmed T, Tauheed I, Akhtar M, Rahman SIA, Khaton F, Ahmmed F, Ferdous J, Afrad MH, Kawser Z, Hossain M, Khondaker R, Hasnat MA, Sumon MA, Rashed A, Ghosh S, Calderwood SB, Charles RC, Ryan ET, Khatri P, Maecker HT, Obermoser G, Pulendran B, Clemens JD, Banu S, Shirin T, LaRocque RC, Harris JB, Bhuiyan TR, Chowdhury F, Qadri F. Disease characteristics and serological responses in patients with differing severity of COVID-19 infection: A longitudinal cohort study in Dhaka, Bangladesh. PLoS Negl Trop Dis. 2022 Jan 04; 16(1):e0010102. PMID: 34982773.
    Citations:    Fields:    
  2. Dugdale CM, Rubins DM, Lee H, McCluskey SM, Ryan ET, Kotton CN, Hurtado RM, Ciaranello AL, Barshak MB, McEvoy DS, Nelson SB, Basgoz N, Lazarus JE, Ivers LC, Reedy JL, Hysell KM, Lemieux JE, Heller HM, Dutta S, Albin JS, Brown TS, Miller AL, Calderwood SB, Walensky RP, Zachary KC, Hooper DC, Hyle EP, Shenoy ES. Coronavirus Disease 2019 (COVID-19) Diagnostic Clinical Decision Support: A Pre-Post Implementation Study of CORAL (COvid Risk cALculator). Clin Infect Dis. 2021 12 16; 73(12):2248-2256. PMID: 33564833.
    Citations: 4     Fields:    Translation:HumansAnimals
  3. Turbett SE, Becker M, Belford B, Kelly M, Desrosiers L, Oliver E, Branda JA, Walters M, Walker AT, LaRocque R, Ryan ET. Evaluation of Candida auris acquisition in U.S. international travelers using a culture-based screening protocol1. J Travel Med. 2021 Dec 07. PMID: 34875080.
    Citations:    Fields:    
  4. Nabel KG, Clark SA, Shankar S, Pan J, Clark LE, Yang P, Coscia A, McKay LGA, Varnum HH, Brusic V, Tolan NV, Zhou G, Desjardins M, Turbett SE, Kanjilal S, Sherman AC, Dighe A, LaRocque RC, Ryan ET, Tylek C, Cohen-Solal JF, Darcy AT, Tavella D, Clabbers A, Fan Y, Griffiths A, Correia IR, Seagal J, Baden LR, Charles RC, Abraham J. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science. 2021 Dec 02; eabl6251. PMID: 34855508.
    Citations: 1     Fields:    
  5. Cole AJ, Slutzman JE, Ryan ET, Lev MH, Eng G. Case 34-2021: A 38-Year-Old Man with Altered Mental Status and New Onset of Seizures. N Engl J Med. 2021 Nov 11; 385(20):1894-1902. PMID: 34758256.
    Citations:    Fields:    Translation:Humans
  6. Meisel PL, DiFiori JP, Côté J, Nguyen JT, Brenner JS, Malina RM, Ryan E, Güllich A. Age of Early Specialization, Competitive Volume, Injury, and Sleep Habits in Youth Sport: A Preliminary Study of US Youth Basketball. Sports Health. 2022 Jan-Feb; 14(1):30-44. PMID: 34753335.
    Citations: 1     Fields:    Translation:Humans
  7. Jeon S, Kelly M, Yun J, Lee B, Park M, Whang Y, Lee C, Halvorsen YD, Verma S, Charles RC, Harris JB, Calderwood SB, Leung DT, Bhuiyan TR, Qadri F, Kamruzzaman M, Cho S, Vann WF, Xu P, Kovác P, Ganapathy R, Lynch J, Ryan ET. Scalable production and immunogenicity of a cholera conjugate vaccine. Vaccine. 2021 Nov 16; 39(47):6936-6946. PMID: 34716040.
    Citations:    Fields:    
  8. Ryan ET, Leung DT, Jensen O, Weil AA, Bhuiyan TR, Khan AI, Chowdhury F, LaRocque RC, Harris JB, Calderwood SB, Qadri F, Charles RC. Systemic, Mucosal, and Memory Immune Responses following Cholera. Trop Med Infect Dis. 2021 Oct 27; 6(4). PMID: 34842841.
    Citations:    
  9. Levade I, Khan AI, Chowdhury F, Calderwood SB, Ryan ET, Harris JB, LaRocque RC, Bhuiyan TR, Qadri F, Weil AA, Shapiro BJ. A Combination of Metagenomic and Cultivation Approaches Reveals Hypermutator Phenotypes within Vibrio cholerae-Infected Patients. mSystems. 2021 Aug 31; 6(4):e0088921. PMID: 34427503.
    Citations:    
  10. Chac D, Bhuiyan TR, Saha A, Alam MM, Salma U, Jahan N, Chowdhury F, Khan AI, Ryan ET, LaRocque R, Harris JB, Qadri F, Weil AA. Gut Microbiota and Development of Vibrio cholerae-Specific Long-Term Memory B Cells in Adults after Whole-Cell Killed Oral Cholera Vaccine. Infect Immun. 2021 08 16; 89(9):e0021721. PMID: 34228490.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
  11. Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, Sanmiguel J, Estelien R, Michalson KT, Diop C, Maciorowski D, Dereuddre-Bosquet N, Cavarelli M, Gallouët AS, Naninck T, Kahlaoui N, Lemaitre J, Qi W, Hudspeth E, Cucalon A, Dyer CD, Pampena MB, Knox JJ, LaRocque RC, Charles RC, Li D, Kim M, Sheridan A, Storm N, Johnson RI, Feldman J, Hauser BM, Contreras V, Marlin R, Tsong Fang RH, Chapon C, van der Werf S, Zinn E, Ryan A, Kobayashi DT, Chauhan R, McGlynn M, Ryan ET, Schmidt AG, Price B, Honko A, Griffiths A, Yaghmour S, Hodge R, Betts MR, Freeman MW, Wilson JM, Le Grand R, Vandenberghe LH. An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host Microbe. 2021 09 08; 29(9):1437-1453.e8. PMID: 34428428.
    Citations: 4     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  12. Aktar A, Rahman MA, Afrin S, Akter A, Uddin T, Yasmin T, Sami MIN, Dash P, Jahan SR, Chowdhury F, Khan AI, LaRocque RC, Charles RC, Bhuiyan TR, Mandlik A, Kelly M, Kovác P, Xu P, Calderwood SB, Harris JB, Qadri F, Ryan ET. Correction: Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh. PLoS Negl Trop Dis. 2021 Jul; 15(7):e0009616. PMID: 34280200.
    Citations:    Fields:    
  13. Kamruzzaman M, Kelly M, Charles RC, Harris JB, Calderwood SB, Akter A, Biswas R, Kaisar MH, Bhuiyan TR, Ivers LC, Ternier R, Jerome JG, Pfister HB, Lu X, Soliman SE, Ruttens B, Saksena R, Mecárová J, Cížová A, Qadri F, Bystrický S, Kovác P, Xu P, Ryan ET. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139. mSphere. 2021 08 25; 6(4):e0011421. PMID: 34232076.
    Citations:    Fields:    
  14. Anahtar MN, Shaw BM, Slater D, Byrne EH, Botti-Lodovico Y, Adams G, Schaffner SF, Eversley J, McGrath GEG, Gogakos T, Lennerz J, Marble HD, Ritterhouse LL, Batten JM, Georgantas NZ, Pellerin R, Signorelli S, Thierauf J, Kemball M, Happi C, Grant DS, Ndiaye D, Siddle KJ, Mehta SB, Harris JB, Ryan ET, Pierce VM, LaRocque RC, Lemieux JE, Sabeti PC, Rosenberg ES, Branda JA, Turbett SE. Development of a qualitative real-time RT-PCR assay for the detection of SARS-CoV-2: a guide and case study in setting up an emergency-use, laboratory-developed molecular microbiological assay. J Clin Pathol. 2021 Aug; 74(8):496-503. PMID: 34049977.
    Citations: 2     Fields:    Translation:Humans
  15. Kaisar MH, Bhuiyan MS, Akter A, Saleem D, Iyer AS, Dash P, Hakim A, Chowdhury F, Khan AI, Calderwood SB, Harris JB, Ryan ET, Qadri F, Charles RC, Bhuiyan TR. Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera. mSphere. 2021 04 28; 6(2). PMID: 33910997.
    Citations: 1     Fields:    Translation:HumansCells
  16. Uddin MI, Hossain M, Islam S, Akter A, Nishat NS, Nila TA, Rafique TA, Leung DT, Calderwood SB, Ryan ET, Harris JB, LaRocque RC, Bhuiyan TR, Qadri F. An assessment of potential biomarkers of environment enteropathy and its association with age and microbial infections among children in Bangladesh. PLoS One. 2021; 16(4):e0250446. PMID: 33886672.
    Citations:    Fields:    Translation:Humans
  17. Kauffman RC, Adekunle O, Yu H, Cho A, Nyhoff LE, Kelly M, Harris JB, Bhuiyan TR, Qadri F, Calderwood SB, Charles RC, Ryan ET, Kong J, Wrammert J. Impact of Immunoglobulin Isotype and Epitope on the Functional Properties of Vibrio cholerae O-Specific Polysaccharide-Specific Monoclonal Antibodies. mBio. 2021 04 20; 12(2). PMID: 33879588.
    Citations: 3     Fields:    Translation:Cells
  18. Akter A, Kelly M, Charles RC, Harris JB, Calderwood SB, Bhuiyan TR, Biswas R, Xu P, Kovác P, Qadri F, Ryan ET. Parenteral Vaccination with a Cholera Conjugate Vaccine Boosts Vibriocidal and Anti-OSP Responses in Mice Previously Immunized with an Oral Cholera Vaccine. Am J Trop Med Hyg. 2021 Apr 19. PMID: 33872211.
    Citations:    Fields:    
  19. Bartsch YC, Wang C, Zohar T, Fischinger S, Atyeo C, Burke JS, Kang J, Edlow AG, Fasano A, Baden LR, Nilles EJ, Woolley AE, Karlson EW, Hopke AR, Irimia D, Fischer ES, Ryan ET, Charles RC, Julg BD, Lauffenburger DA, Yonker LM, Alter G. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med. 2021 03; 27(3):454-462. PMID: 33589825.
    Citations: 17     Fields:    Translation:HumansPHPublic Health
  20. Levade I, Saber MM, Midani FS, Chowdhury F, Khan AI, Begum YA, Ryan ET, David LA, Calderwood SB, Harris JB, LaRocque RC, Qadri F, Shapiro BJ, Weil AA. Predicting Vibrio cholerae Infection and Disease Severity Using Metagenomics in a Prospective Cohort Study. J Infect Dis. 2021 02 03; 223(2):342-351. PMID: 32610345.
    Citations: 4     Fields:    Translation:Cells
  21. Zabaleta N, Dai W, Bhatt U, Chichester JA, Sanmiguel J, Estelien R, Michalson KT, Diop C, Maciorowski D, Qi W, Hudspeth E, Cucalon A, Dyer CD, Pampena MB, Knox JJ, LaRocque RC, Charles RC, Li D, Kim M, Sheridan A, Storm N, Johnson RI, Feldman J, Hauser BM, Zinn E, Ryan A, Kobayashi DT, Chauhan R, McGlynn M, Ryan ET, Schmidt AG, Price B, Honko A, Griffiths A, Yaghmour S, Hodge R, Betts MR, Freeman MW, Wilson JM, Vandenberghe LH. Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates. bioRxiv. 2021 Jan 19. PMID: 33442684.
    Citations:    
  22. Walker AT, Gershman MD, Rao SR, LaRocque RC, Ryan ET. Yellow Fever Vaccine Administration at Global TravEpiNet (GTEN) Clinics during a Period of Limited Vaccine Availability in the United States, 2017-2018. Am J Trop Med Hyg. 2021 Jan 18. PMID: 33534766.
    Citations:    Fields:    
  23. Worby CJ, Earl AM, Turbett SE, Becker M, Rao SR, Oliver E, Taylor Walker A, Walters M, Kelly P, Leung DT, Knouse M, Hagmann SHF, Ryan ET, LaRocque RC. Acquisition and Long-term Carriage of Multidrug-Resistant Organisms in US International Travelers. Open Forum Infect Dis. 2020 Dec; 7(12):ofaa543. PMID: 33409326.
    Citations: 3     
  24. Lemieux JE, Siddle KJ, Shaw BM, Loreth C, Schaffner SF, Gladden-Young A, Adams G, Fink T, Tomkins-Tinch CH, Krasilnikova LA, DeRuff KC, Rudy M, Bauer MR, Lagerborg KA, Normandin E, Chapman SB, Reilly SK, Anahtar MN, Lin AE, Carter A, Myhrvold C, Kemball ME, Chaluvadi S, Cusick C, Flowers K, Neumann A, Cerrato F, Farhat M, Slater D, Harris JB, Branda JA, Hooper D, Gaeta JM, Baggett TP, O'Connell J, Gnirke A, Lieberman TD, Philippakis A, Burns M, Brown CM, Luban J, Ryan ET, Turbett SE, LaRocque RC,